Parmar A, Timilshina N, Emmenegger U, Smoragiewicz M, Sander B, Alibhai S, et al. A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancer. CUAJ [Internet]. 2021 Oct. 18 [cited 2026 May 21];16(3):E126-31. Available from: https://cuaj.ca/index.php/journal/article/view/7495